Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

The Prohost Portfolio: Updating the Stock Targets

March 15, 2018 0

Prohost Letter #419 RE-EVALUATION ONLY - The Prohost Portfolio comprises biotechnology and biopharmaceutical companies, that we …

Alnylam Reaches Prohost 2018 Target. Regeneron Negotiates a Lower Price for Praluent

March 13, 2018 0

Alnylam (ALNY) announced that Sanofi Genzyme declined its opt-in for the development and commercialization of the RNAi …

Highlighting Gene Editing Firms

March 12, 2018 0

The Week in Review #19 Targeting the Root-Cause of Diseases - Investing in the Future is …

Trogarzo’s FDA Approval Made Possible Managing Multidrug Resistant HIV 1 Infection

March 8, 2018 0

Extremely important news has come from Montreal, Canada carrying the announcement by Theratechnologies (TSX:TH) and its partner TaiMed …

Regeneron’s Product Dupixant is Shown to Improve the Management of Asthma

March 6, 2018 0

Regeneron’s (REGN) pipeline products have still a lot of good news to announce. The latest is about …

Thanks to Aimmune, You Might Be Able to Eat Peanut Butter by Next Year

March 5, 2018 0

On March 4, 2018, Aimmune Therapeutics (AIMT) – a biopharmaceutical company developing treatments for potentially life-threatening food allergies …

Observing Queer Stories

March 2, 2018 0

Prohost Letter #418 Observing Queer Stories PORTOLA - Portola (PTLA) has been granted approval of an …

ObsEva Announced Positive Results from Its Product Nolasiban for In Vitro Fertilization

February 27, 2018 0

FERTILITY Fertility is what guarantees the presence of humans on the planet Earth. The reproductive system …

The FDA Approves AstraZeneca Checkpoint Inhibitor Imfinzi® for a Lung Cancer. A Probable Partnership Agreement Between Arbutus and Roivant

February 22, 2018 0

The Food and Drug Administration (FDA) approved AstraZeneca (AZN) Checkpoint inhibitor drug Imfinzi® (durvalumab) for patients with unresectable Stage III non-small …

Gilead Collaboration with Sangamo

February 22, 2018 0

Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for …

Portola: Ignoring the Good News. Aimmune Therapeutic’s Drug AR101 Met Its Primary Efficacy Endpoint

February 21, 2018 0

Portola Pharmaceuticals and the CHMP’s Oral Explanations for Andexanet Alfa and Betrixaban Portola (PTLA) announced that the Committee for …

In the Limelight

February 19, 2018 0

The Week in Review #18 The Market - The stock market recuperated most of its losses …

Seattle Genetics and Pieris Pharmaceuticals: A Collaboration to Improve Cancer Immunotherapy

February 15, 2018 0

Seattle Genetics and Pieris pharmaceutical Collaboration Agreement Pieris Pharmaceuticals (PIRS) and Seattle Genetics (SGEN) signed a multi-program immuno-oncology collaboration …

An Early FDA Approval of Vertex’s Cystic Fibrosis Combo Symdeko

February 15, 2018 0

Expected or not, we believe that the news announcing that the U.S. Food and Drug Administration …

Nektar Therapeutics: The Best Example of the “Sell Good News” Reckless Habit

February 14, 2018 0

Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR) Announce Global Development & Commercialization Collaboration for Nektar’s Product …

A Wild Wild Week

February 12, 2018 0

The Week in Review #17 A Wild Wild Week - The stock market looked as if …

Private Lessons and More

February 9, 2018 0

Prohost Letter #417 Private Lessons - These lessons are overdue and we had to do this …

From Stanford: A Step on the Road Toward a Cancer Cure. From Theravance: a Worthwhile Co-Development Agreement with Janssen Biotech

February 7, 2018 0

A Stanford research team investigating a new immunotherapy approach, which consists of injecting tiny amounts of two immuno-stimulating …

The Undiagnosed Market Seizures

February 6, 2018 0

We postponed the Prohost Letter we planned to post this past Monday until the market’s fits come to …

Vertex: Next-Generation Correctors VX-659 and VX-445 for Triple Combinations Promise Significant Clinical Benefits for Around 90% of People with Cystic Fibrosis.

February 1, 2018 0

Vertex (VRTX) announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

The Prohost Portfolio: Updating the Stock Targets

Alnylam Reaches Prohost 2018 Target. Regeneron Negotiates a Lower Price for Praluent

Highlighting Gene Editing Firms

Trogarzo’s FDA Approval Made Possible Managing Multidrug Resistant HIV 1 Infection

Regeneron’s Product Dupixant is Shown to Improve the Management of Asthma

Thanks to Aimmune, You Might Be Able to Eat Peanut Butter by Next Year

Observing Queer Stories

ObsEva Announced Positive Results from Its Product Nolasiban for In Vitro Fertilization

The FDA Approves AstraZeneca Checkpoint Inhibitor Imfinzi® for a Lung Cancer. A Probable Partnership Agreement Between Arbutus and Roivant

Gilead Collaboration with Sangamo

Portola: Ignoring the Good News. Aimmune Therapeutic’s Drug AR101 Met Its Primary Efficacy Endpoint

In the Limelight

Seattle Genetics and Pieris Pharmaceuticals: A Collaboration to Improve Cancer Immunotherapy

An Early FDA Approval of Vertex’s Cystic Fibrosis Combo Symdeko

Nektar Therapeutics: The Best Example of the “Sell Good News” Reckless Habit

A Wild Wild Week

Private Lessons and More

From Stanford: A Step on the Road Toward a Cancer Cure. From Theravance: a Worthwhile Co-Development Agreement with Janssen Biotech

The Undiagnosed Market Seizures

Vertex: Next-Generation Correctors VX-659 and VX-445 for Triple Combinations Promise Significant Clinical Benefits for Around 90% of People with Cystic Fibrosis.